Study of V117957 in Overactive Bladder Syndrome
- Registration Number
- NCT06024642
- Lead Sponsor
- Imbrium Therapeutics
- Brief Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 51
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description V117957 V117957 - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Change From Baseline in Micturition Episode Components (Micturition, Incontinence, and Urgency) Per 24 Hours. Baseline, Weeks 2, and 8 Subjects were asked to record all micturition episode components into a daily electronic diary during the 3 to 7 days prior to each scheduled clinic visit.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (12)
Arizona Urology Specialists, PLLC
🇺🇸Tucson, Arizona, United States
Hope Clinical Research, LLC
🇺🇸Canoga Park, California, United States
ARK Clinical Research
🇺🇸Long Beach, California, United States
Urology Group of Southern California
🇺🇸Los Angeles, California, United States
Providea Health Partners, LLC
🇺🇸Evergreen Park, Illinois, United States
DelRicht Research
🇺🇸New Orleans, Louisiana, United States
Ochsner LSU Health Shreveport - Regional Urology
🇺🇸Shreveport, Louisiana, United States
Boston Clinical Trials
🇺🇸Boston, Massachusetts, United States
Bay State Clinical Trials, Inc.
🇺🇸Watertown, Massachusetts, United States
AccuMed Research Associates
🇺🇸Garden City, New York, United States
Scroll for more (2 remaining)Arizona Urology Specialists, PLLC🇺🇸Tucson, Arizona, United States